

**Sastry K Anandam & Co. LLP.**  
Chartered Accountants  
M56B, LGF, Shop No.5, Malviya Nagar, New Delhi-110017  
Tel: +91(11) 41042489, Website: [www.sastryanandam.co.in](http://www.sastryanandam.co.in)

**Independent Auditor's Report**

To the Members of AMBEY LABORATORIES LIMITED

**Report on the Financial Statements**

We have audited the accompanying financial statements of AMBEY LABORATORIES LIMITED ("the Company"), which comprise the Balance Sheet as at March 31, 2021, the statement of Profit and Loss, and a summary of the significant accounting policies and other explanatory information.

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We, have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143 (10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedure that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the



aforsaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, and its profit/loss and its cash flows for the year ended on that date.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143. of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143 (3) of the Act, we report:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books

c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure B'.

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has some pending litigations against/by the company in due course of its business with its customers/vendors and tax authorities/Govt. authorities. But as per the explanation and information provided to us, these would not impact its financial position as directors are hopeful to get the decisions in their favor.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

**For Sastry K Anandam & Co. LLP**

**Chartered Accountants**

Firm Reg. No.: 000179N/1500051

UDIN: 21514021AAYAAIN8982

**CA Krishna Kumar**

**(Partner)**

M. No. 514021

Place: Delhi

Date: 02/09/2021

## Annexure 'A'

**The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".**

We report that:

- a. The company has maintained proper records showing full particulars, including quantitative details and situation of its fixed assets.
- b. As explained to us, fixed assets have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
- c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the company.
- d. As explained to us, inventories have been physically verified during the year by the management at reasonable intervals. No material discrepancy was noticed on physical verification of stocks by the management as compared to book records.
- e. According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties listed in the register maintained under Section 189 of the Companies Act, 2013. Consequently, the provisions of clauses iii (a), (b) and (c) of the order are not applicable to the Company.
- f. In respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
- g. The company has not accepted any deposits from the public covered under sections 73 to 76 of the Companies Act, 2013.
- h. As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013.
- i. According to the records of the company, undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income-tax, Sales-tax, Service Tax, Custom Duty, Excise Duty, value added "tax, cess and any other statutory dues to the extent applicable, have generally been regularly deposited with the appropriate authorities.
- j. In our opinion and according to the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to a financial institution, bank, Government or debenture holder, as applicable to the company.
- k. Based on our audit procedures and according to the information given by the management, the company has not raised any money by way of initial public offer or further public offer (including debt instruments) or taken any term loan during the year.
- l. According to the information and explanations given to us, we report that no material fraud by the company or by its officers or employees has been noticed or reported during the year.
- m. Managerial remuneration has been paid and provided by the company in accordance with the requisite approvals mandated by the provisions of Section 197 of the Act read ' with Schedule V to the



Act.

n. The company is not a Nidhi Company. Therefore clause xii) of the order is not applicable to the company.

o. According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards.

p. The company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review.

q. The company has not entered into non-cash transactions with directors or persons connected with him.

r. The company is not required to be registered under section 45-IA of the Reserve Bank of India A 1934.

**For Sastry K Anandam & Co. LLP**

**Chartered Accountants**

Firm Reg. No.: 000179N/N500051

UDIN: 21514021AAAANIN8982

**CA Krishna Kumar**

**(Partner)**

M. No. 514021

Place: Delhi

Date: 02/09/2021



## Annexure 'B'

### Report on Internal Financial Controls over Financial Reporting

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **AMBEY LABORATORIES LIMITED** ("the Company") as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

### Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



### Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

1. pertains to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Sastry K Anandam & Co. LLP**

Chartered Accountants

Firm Reg. No.: 000179N/N500051

CA Krishna Kumar

(Partner)

M. No. 514021

Place: Delhi

Date: 02/09/2021



Ambey Laboratories Limited  
Balance Sheet as at 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

	Note	As at March 31, 2021	As at March 31, 2020
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholder's Funds</b>			
Share Capital	3	48,935,000	48,935,000
Reserves and Surplus	4	(196,887,623)	(226,031,528)
		<u>(147,952,623)</u>	<u>(177,096,528)</u>
<b>Non-Current Liabilities</b>			
Long-Term Borrowing	5	301,028,462	303,246,806
Deferred Tax Liability	6	-	223,961
		<u>301,028,462</u>	<u>303,470,767</u>
<b>Current Liabilities</b>			
Short-Term Borrowing	7	-	-
Trade payables	8	-	-
Total outstanding dues of micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises		161,790,633	191,560,283
Other Current Liabilities	9	50,632,501	97,228,238
Short Term Provisions	10	9,068,158	4,723,838
		<u>221,491,292</u>	<u>293,512,359</u>
<b>Total</b>		<u><u>374,567,132</u></u>	<u><u>419,886,598</u></u>
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
<b>Property, plant and equipment</b>			
Tangible Assets	11(a)	145,737,811	163,312,506
Intangible Assets	11(b)	12,747,478	17,171,642
Capital Work-in-progress		9,511,640	7,661,640
Deferred Tax Assets (Net)	6	905,850	-
Long Term Loans & Advances	12	4,585,414	13,480,574
		<u>173,488,194</u>	<u>201,626,363</u>
<b>Current Assets</b>			
Inventories	13	87,323,520	137,900,431
Trade Receivables	14	69,297,360	49,418,943
Cash and Cash Equivalents	15	5,085,786	4,251,940
Short Term Loan & Advances	16	28,025,472	24,793,405
Other Current Assets	17	11,346,799	1,895,517
		<u>201,078,938</u>	<u>218,260,236</u>
<b>Total</b>		<u><u>374,567,132</u></u>	<u><u>419,886,598</u></u>
Summary of significant accounting policies	2		

The accompanying notes are an integral part of these financial statements.

As per our report of even date

For Sastry K Anandam & Co. LLP  
Chartered Accountants

Firm Registration No.: 000179N/N500051  
UDIN:21514021AAAN8982

CA Krishna Kumar  
(Partner)  
M.No. 514021

Place : New Delhi  
Date : 02.09.2021

For and on behalf of the Board of Directors of

Ambey Laboratories Limited

CIN: 074899DL1985PLC020490

Arpit Gupta  
Director  
DIN: 01876092

Place : New Delhi  
Date : 02.09.2021

Archit Gupta  
Director  
DIN: 00378409

Place : New Delhi  
Date : 02.09.2021


DIRECTOR

**Ambey Laboratories Limited**  
**Statement of Profit and Loss for the year ended 31st March, 2021**  
 (All amounts are in Indian Rupees, unless otherwise stated)

	Note	Year ended March 31, 2021	Year ended March 31, 2020
<b>Income:</b>			
Revenue from operations			
Other Income	18	817,393,619	670,171,223
<b>Total</b>	19	<b>4,878,937</b>	<b>23,599,149</b>
		<b>822,272,556</b>	<b>693,770,372</b>
<b>Expenses:</b>			
Cost of material consumed	20	608,671,490	571,537,813
Changes in inventories of work-in-progress, finished goods	21	18,755,418	(42,032,122)
Employee benefit expense	22	56,009,854	41,928,388
Depreciation and amortization expense	23	32,222,243	23,541,025
Finance cost	24	41,102,809	50,284,509
Other expenses	25	37,495,380	45,303,046
<b>Total</b>		<b>794,257,194</b>	<b>690,562,659</b>
<b>Profit before tax</b>		<b>28,015,362</b>	<b>3,207,713</b>
<b>Tax expense:</b>			
Current tax		4,676,325	-
Deferred tax charge/ (benefit)	6	(1,129,811)	1,047,340
Mat credit entitlement		(4,676,325)	-
		<b>(1,129,811)</b>	<b>1,047,340</b>
<b>Profit/ (loss) for the year</b>		<b>29,145,173</b>	<b>2,160,373</b>
<b>Earnings per equity share [Nominal value per share Rs. 10 (previous year Rs.10 )]:</b>	27		
Basic earnings per share		59.56	4.41
Diluted earnings per share		59.56	4.41
Summary of significant accounting policies	2		

The accompanying notes are an integral part of these financial statements.

As per our report of even date

For Sastry K Anandam & Co. LLP  
 Chartered Accountants  
 Firm Registration No.: 000179N/N500051  
 UDIN:21514021AAAAIN8982  
  
 CA Krishna Kumar  
 (Partner)  
 M.No. 514021

For and on behalf of the Board of Directors of  
 Ambey Laboratories Limited  
 CIN: U74899DL1985PLC020490

For AMBEY LABORATORIES LIMITED  
  
 Arpit Gupta  
 Director  
 DIN: 01876092  
  
 Archit Gupta  
 Director  
 DIN: 00378409  
 DIRECTION

Place : New Delhi  
 Date : 02.09.2021

Place : New Delhi  
 Date : 02.09.2021

Place : New Delhi  
 Date : 02.09.2021



Ambey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

1 Background

Ambey Laboratories Limited ('the Company') is a Company limited by shares domiciled in India, with its registered office situated at G-2, Vikas Apartment, 34/1 East Punjabi Bagh, New Delhi-110026. The Company has been incorporated under Companies Act, 1956 (substituted by Companies Act, 2013) on 20 Mar 1985 (CIN U74899DL1985PLC020490). The Company primarily engaged in the business of manufacturing and distribution of home hygiene products under the brand name 'Trishul'.

2 Summary of significant accounting policies

i Basis of Preparation

The financial statements have been prepared in accordance with generally accepted accounting principles in India under the historical cost convention on an accrual basis in compliance with all material aspects of the Accounting Standards (AS) notified under section 133 of the Companies Act 2013, read together with Rule 7 of the Companies (Accounts) Rules 2014. The accounting policies adopted in the preparation of financial statements have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy until now (hitherto) in use with those of previous year.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

ii Use of estimates

The preparation of financial statements requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities, at the end of the reporting period. Although, these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

iii Property, Plant and Equipment - Tangible assets

Tangible assets are stated at cost, less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price, borrowing costs, if capitalization criteria are met and any cost attributable to bringing the assets to its working condition for its intended use which includes taxes, freight, and installation and allocated incidental expenditure during acquisition and exclusive of input tax credit (IGST/CGST and SGST) or other tax credit available to the Company.

When parts of an item of tangible assets have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Subsequent expenditure relating to tangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

iii Property, Plant and Equipment - Intangible assets

Acquired intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

iv Depreciation on property, plant and equipment

Based on management's evaluation, useful life prescribed in Schedule II of the Companies Act, 2013 represent actual useful life of property, plant and equipment. The Company uses written down value method and has used following useful lives to provide depreciation of different class of its property, plant and equipment.

For AMBEY LABORATORIES LIMITED

For AMBEY LABORATORIES LIMITED

DIRECTOR

DIRECTOR



**Ambey Laboratories Limited**  
**Statement of Profit and Loss for the year ended 31st March, 2021**  
(All amounts are in Indian Rupees, unless otherwise stated)

The Company has adopted Schedule II to the Companies Act, 2013 which requires identification and determination of separate useful life for each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset. (Component Accounting)

Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard from tangible assets is provided for upto the date of sale, deduction or discard of tangible assets as the case may be.

Assets costing less than Rs. 5,000 are depreciated @ 100% in the year of put to use.

v Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognised wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets' net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital.

After impairment, depreciation/amortization is provided on the revised carrying amount of the asset over its remaining useful life.

vi Foreign currency translation

**Initial recognition:**

Foreign currency transactions are recorded in the reporting currency by applying the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

**Conversion:**

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when such values were determined.

**Exchange differences:**

Exchange differences arising on the settlement of monetary items or on reporting the Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or as expenses in the year in which they occur.

vii Revenue recognition

Revenue is recognised to the extent, that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

**Revenue from sale of goods**

Revenue from sale of goods is recognised when the significant risks and rewards of ownership of the goods are transferred to the buyer.

**Interest income**

Interest income is recognised on a time proportion basis taking into account the amount outstanding and applicable interest rate.

**Dividend Income**

Dividend income on shares of corporate bodies and units of mutual funds is accounted on accrual basis when the Company's right to receive dividend is established.

**Revenue from sale of services**

Revenue from sale of services are accounted based on stage of completion of assignments, when there is reasonable certainty of its ultimate realisation.

For AMBEY LABORATORIES LIMITED

*Araw Gun*

For AMBEY LABORATORIES LIMITED

*AA Gun*

DIRECTOR

DIRECTOR



**Ambey Laboratories Limited**  
**Statement of Profit and Loss for the year ended 31st March, 2021**  
(All amounts are in Indian Rupees, unless otherwise stated)

viii Investment

**Non-Current Investment**

Non-current investments are investments intended to be held for a period of more than a year. Non-current investments are carried individually at cost less provision for diminution, other than temporary, in the value of such investments.

**Current Investment**

Current investments are investments intended to be held for a period of less than a year. Current investments are stated at the lower of cost and market value, determined on an individual investment basis.

ix Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with banks. Bank overdrafts are shown within borrowings in current liabilities in balance sheet.

x Inventories

Inventories are valued at lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct cost and related overheads.

Provision of obsolescence on inventories is considered on the basis of management's estimate based on demand and market of the inventories.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

xi Income taxes

Tax expense for the period comprises of current tax, deferred tax and Minimum alternate tax credit considered in determining the net profit or loss for the year.

**Current tax**

Provision for current tax is recognized on the basis of estimated taxable income for the current accounting year in accordance with the Income-tax Act, 1961.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts, and there is an intention to settle the asset and the liability on a net basis.

**Deferred tax**

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted as of the reporting date.

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each balance sheet date and are written-down or written up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

At each reporting date, the Company reassesses the unrecognized deferred tax assets, if any.

For AMBEY LABORATORIES LIMITED

*Manoj Kumar*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*Arun Kumar*  
DIRECTOR



Ambeey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

**Minimum alternate tax**

Minimum alternate tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period.

xii **Leases**

**Operating leases - As a lessee**

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to Statement of Profit and Loss on a straight-line basis over the period of lease.

xiii **Provisions, Contingent Liability and Contingent Asset**

**Provisions**

The Company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation.

**Contingent liabilities**

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

**Contingent assets**

Contingent assets are neither recorded nor disclosed in the financial statements.

xiv **Earnings Per Share**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

For AMBEY LABORATORIES LIMITED

*Arun Kumar*

For AMBEY LABORATORIES LIMITED

DIRECTOR

*Arun Kumar*  
DIRECTOR



Ambey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

3 Share capital

The Company has only one class of share capital having a par value of ₹ 100 per share, referred to herein as equity shares.

	March 31, 2021	March 31, 2020
<u>Authorized</u>		
7,00,000 Equity shares of 100/- each	70,000,000	70,000,000
	<u>70,000,000</u>	<u>70,000,000</u>
<u>Issued, subscribed and paid up</u>		
4,89,350 Equity shares of 100/- each	48,935,000	48,935,000
	<u>48,935,000</u>	<u>48,935,000</u>

(a) Reconciliation of shares outstanding at the beginning and at the end of the year

	March 31, 2021		March 31, 2020	
	Number of shares	Amount	Number of shares	Amount
Equity shares				
Outstanding as at the beginning of the year	489,350	48,935,000	489,350	48,935,000
Add: Issued during the year	-	-	-	-
Outstanding as at the end of the year	<u>489,350</u>	<u>48,935,000</u>	<u>489,350</u>	<u>48,935,000</u>

(b) Rights, preferences and restrictions attached to shares

The Company has only one class of equity shares having par value of Rs. 100 per share. Each shareholder is entitled to one vote per share held. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(c) Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company

Name of the shareholder	March 31, 2021		March 31, 2020	
	Number of shares	% of holding	Number of shares	% of holding
Equity shares				
Anil Gupta	219,295	44.81%	219,295	44.81%
Archit Gupta	114,630	23.42%	114,630	23.42%
Arpit Gupta	114,630	23.42%	114,630	23.42%

As per records of the Company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

(d) Company has not issued any shares as bonus shares during the period of five years immediately preceding the reporting date.

(e) No class of share have been bought back by the Company during the period of five years immediately preceding the reporting date.

4 Reserves and surplus

	March 31, 2021	March 31, 2020
Surplus/(deficit) in the Statement of Profit and Loss		
Opening balance	(226,031,528)	(244,979,294)
Add: Profit for the year	29,145,173	2,160,373
Add: Prior period adjustment	40,278	16,787,393
Less : Other adjustment	(41,546)	
Closing balance	<u>(196,887,623)</u>	<u>(226,031,528)</u>

For AMBEY LABORATORIES LIMITED

*AA Gupta*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*Arpit Gupta*  
DIRECTOR



Ambey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

	March 31, 2021	March 31, 2020
<b>5 Long Term Borrowings</b>		
Secured		
Term Loan from Banks/ Financial Institutions	141,347,954	135,517,173
Vehicle loan (Refer note below)	197,628	334,908
Unsecured		
Term Loan from Financial Institution	15,438,884	-
Loan for capital assets	-	3,457,286
Loan from directors and relatives	129,996,654	133,150,764
Other long term loans	14,047,342	30,786,675
	<u>301,028,462</u>	<u>303,246,806</u>

Note:

1 Secured

(i) Term loan represent the loan from:

- a). Assets Care & Recontraction Enterprise Ltd amounting to Rs. 22,51,00,000 (Settlement amount toward the total dues of Rs. 15,50,00,000 to ICICI Bank as on October 16, 2018). It carries interest rate of "1 Base Rate+3%+6%-10%\*(Default Rate) for Cash Credit, Term Loan & Developed LC.  
b). HSBC Bank amounting to Rs. 2,17,00,000 [Settlement amount toward the total overdraft dues of Rs. 3,00,00,000 (Principal) as on June 30, 2018].

(ii) Vehicle loan represent the loan from:

- a). ICICI Bank amounting to Rs. 16,00,000. It carries interest rate of 10.41% p.a.

Primary security:

Loan from Assets Care & Recontraction Enterprise Ltd secured by:

Pari passu charge on current asset of the Company.

Pari passu charge on Factory Land & Building SPI/5, Sotanala Industrial Area, Behror, District Alwar, Rajasthan-301701.

Pari passu charge on property situated at G-2, 34/1, Vikas Aptt., Punjabi Bagh, Delhi.

Exclusive charge on movable assets of the Company.

Vehicle loan

Vehicle loans are secured against hypothecation of respective vehicle purchased by the Company.

Collateral security:

Loan from Assets Care & Recontraction Enterprise Ltd are further secured by personal Guarantee of Mr. Anil Gupta, Mr. Archit Gupta, Mr. Arpit Gupta and Anil Gupta HUF.

2 Unsecured

(i) Term loan represent the business loan from:

- a). Oxyzo Financial Services Pvt Ltd amounting to Rs. 1,00,00,000. It carries interest rate of 18% per annum.  
b). Oxyzo Financial Services Pvt Ltd amounting to Rs. 95,00,000. It carries interest rate of 18% per annum.  
c). Oxyzo Financial Services Pvt Ltd amounting to Rs. 3,00,00,000. It carries interest rate of 30% per annum. (Paid-off in current FY 2020-21).

(ii) Loan for capital asset represent the capital financing from:

- a). Oxyzo Financial Services Pvt Ltd amounting to Rs. 39,00,000. It carries interest rate of 21% per annum. (Paid-off in current FY 2020-21).

6 Deferred tax liability (net)

	March 31, 2021	Charge/(benefit) for the year	March 31, 2020
Deferred tax liability/(asset)	(905,850)	(1,129,811)	223,961
Difference between book depreciation and tax depreciation			
Total	<u>(905,850)</u>	<u>(1,129,811)</u>	<u>223,961</u>

7 Short term borrowings

	March 31, 2021	March 31, 2020
Secured		
From banks		
Cash credit and overdraft facilities from bank	-	-
Total	<u>-</u>	<u>-</u>

8 Trade payables

	March 31, 2021	March 31, 2020
Total outstanding dues of micro enterprises and small enterprises	161,790,633	191,560,283
Total outstanding dues of creditors other than micro enterprises and small enterprises	161,790,633	191,560,283
Total	<u>161,790,633</u>	<u>191,560,283</u>

9 Other current liabilities

	March 31, 2021	March 31, 2020
Current maturities of long-term borrowings	31,354,414	44,517,259
Advance from customer	1,008,810	33,477,123
Statutory dues payable	3,733,013	5,698,486
Payable to employees	9,708,842	7,134,058
Other expenses payable	466,061	1,146,583
Other Current Liabilities	4,361,361	5,254,729
Total	<u>50,632,501</u>	<u>97,228,238</u>

10 Short term provisions

	March 31, 2021	March 31, 2020
Provision for Income tax [net of advance tax Rs. 26,87,408 (Previous Year Rs. 23,76,162)]	9,068,158	4,723,838
Total	<u>9,068,158</u>	<u>4,723,838</u>

For AMBEY LABORATORIES LIMITED

For AMBEY LABORATORIES LIMITED

*AA. Gupta*  
DIRECTOR

*Archit Gupta*  
DIRECTOR



Ambeey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

11(a) Property, plant and equipment

Particulars	Land	Building	Building Temporary Structure	Plant and Machinery	Office equipments	Computers and printers	Furniture & Fixture	Electrical Installation and Equipment	Motor Vehicle	Laboratory Equipment	Total
<b>Own assets:</b>											
<b>Gross block</b>											
Balance as at 31 March 2019	4,950,000	69,384,510	-	194,529,863	2,590,723	1,680,075	1,609,380	11,526,930	6,575,448	2,863,246	295,710,175
Additions	-	1,509,889	-	82,088,736	58,773	45,763	-	-	-	-	83,703,161
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2020	4,950,000	70,894,399	-	276,618,599	2,649,496	1,725,838	1,609,380	11,526,930	6,575,448	2,863,246	379,413,336
Additions	-	2,467,473	-	6,828,794	286,160	117,158	523,800	-	-	-	10,223,385
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2021	4,950,000	73,361,872	-	283,447,393	2,935,656	1,842,996	2,133,180	11,526,930	6,575,448	2,863,246	389,636,721
<b>Accumulated depreciation</b>											
Balance as at 31 March 2019	-	38,456,561	-	131,399,932	2,212,470	1,620,404	1,392,032	9,877,155	5,170,995	2,578,363	192,707,912
Depreciation during the year	-	3,027,763	-	19,275,182	146,627	21,097	56,511	427,127	438,611	-	23,392,918
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2020	-	41,484,324	-	150,675,114	2,359,097	1,641,501	1,448,543	10,304,282	5,609,606	2,578,363	216,100,830
Depreciation during the year	-	2,666,570	-	24,193,026	116,515	51,263	83,595	384,523	286,344	36,243	27,798,079
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2021	-	44,150,894	-	174,868,140	2,475,612	1,692,764	1,532,138	10,688,805	5,875,950	2,614,606	243,898,909
<b>Net block</b>											
Balance as at 31 March 2020	4,950,000	29,410,075	-	125,943,485	290,399	84,337	160,837	1,222,648	965,842	284,883	163,312,506
Balance as at 31 March 2021	4,950,000	29,210,978	-	108,579,253	460,044	150,232	601,042	838,125	699,498	248,640	145,737,811



For AMBEY LABORATORIES LIMITED

*[Signature]*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*[Signature]*  
DIRECTOR

Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2021

(All amounts are in Indian Rupees, unless otherwise stated)

11(a) Intangible Assets

Particulars	Computer Software	Total	
<b>Own assets:</b>			
<b>Gross block</b>			
Balance as at 31 March 2019	19,002,133	19,002,133	19,002,133
Additions	29,650	29,650	29,650
Disposals	-	-	-
Balance as at 31 March 2020	19,031,783	19,031,783	19,031,783.00
Additions	-	-	-
Disposals	-	-	-
Balance as at 31 March 2021	19,031,783	19,031,783	19,031,783.00
<b>Accumulated depreciation</b>			
Balance as at 31 March 2019	1,712,034	1,712,034	1,712,034
Depreciation during the year	148,107	148,107	148,107
Disposals	-	-	-
Balance as at 31 March 2020	1,860,141	1,860,141	1,860,141
Depreciation during the year	4,424,164	4,424,164	4,424,164
Disposals	-	-	-
Balance as at 31 March 2021	6,284,305	6,284,305	6,284,305
<b>Net block</b>			
Balance as at 31 March 2020	17,171,642	17,171,642	17,171,642.00
Balance as at 31 March 2021	12,747,478	12,747,478	12,747,478

For AMBEY LABORATORIES LIMITED

*Manoj Kumar*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*Ankur Choudhary*

DIRECTOR





Ambeey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

	March 31, 2021	March 31, 2020
<b>12 Long Term loans and advances</b>		
Security deposit	3,451,511	2,976,511
Other long term advances	1,133,903	10,504,063
<b>Total</b>	<b>4,585,414</b>	<b>13,480,574</b>
<b>13 Inventories</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
(Valued at lower of cost and net realizable value, unless stated otherwise)		
Stock-in-trade	87,323,520	137,900,431
<b>Total</b>	<b>87,323,520</b>	<b>137,900,431</b>
<b>14 Trade receivable</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
(Unsecured, considered good)		
Outstanding for a period exceeding six months from the date they are due for payment	-	-
Others	69,297,360	49,418,943
<b>Total</b>	<b>69,297,360</b>	<b>49,418,943</b>
<b>15 Cash and bank balances</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
Cash and cash equivalents		
Cash on hand	3,386,589	4,205,348
Balances with bank on current accounts	1,699,198	46,592
<b>Total</b>	<b>5,085,786</b>	<b>4,251,940</b>
<b>16 Short term loans and advances</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
Advance to suppliers	22,272,286	18,761,126
Capital advances	1,029,600	1,035,455
Advances to employees	1,589,319	1,143,986
Balance with Government authorities	3,134,268	1,651,157
Other advances	-	2,201,681
<b>Total</b>	<b>28,025,472</b>	<b>24,793,405</b>
<b>17 Other current assets</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
Bank deposits with maturity of more than 12 months	10,000	10,000
Imperest	5,923,409	975,126
Prepaid expenses	646,013	894,482
Mat credit entitlement	4,676,325	-
Other current assets	91,052	15,909
<b>Total</b>	<b>11,346,799</b>	<b>1,895,517</b>

For AMBEY LABORATORIES LIMITED

For AMBEY LABORATORIES LIMITED

DIRECTOR

DIRECTOR



Ambeey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

18 Revenue from operations

Sale of products  
Manufactured goods  
Total

Year ended March 31, 2021	Year ended March 31, 2020
817,393,619	670,171,223
<b>817,393,619</b>	<b>670,171,223</b>

19 Other income

Commission income  
Liabilities written off  
Interest income  
Export incentives  
Foreign exchange fluctuation  
Other miscellaneous income  
Total

Year ended March 31, 2021	Year ended March 31, 2020
1,972,112	-
-	23,266,892
402,685	-
2,321,494	-
182,646	100,241
-	232,016
<b>4,878,937</b>	<b>23,599,149</b>

20 Cost of material consumed

Inventory at the beginning of the year  
Purchases during the year  
Inventory at the end of the year  
Total

Year ended March 31, 2021	Year ended March 31, 2020
42,156,794	45,823,810
576,849,997	567,870,797
10,335,301	42,156,794
<b>608,671,490</b>	<b>571,537,813</b>

21 Changes in inventories of work-in-progress, finished goods

Inventory at the beginning of the year  
Finished goods  
Work-in-progress

Year ended March 31, 2021	Year ended March 31, 2020
42,342,753	53,711,515
53,400,884	-
95,743,637	53,711,515

Inventory at the end of the year  
Finished goods  
Work-in-progress

18,908,219	42,342,753
58,080,000	53,400,884
76,988,219	95,743,637

Total

<b>18,755,418</b>	<b>(42,032,122)</b>
-------------------	---------------------

22 Employee benefits expense

Salaries, wages, bonus and other allowances  
Contribution to provident and other funds  
Staff welfare  
Directors remuneration  
Total

Year ended March 31, 2021	Year ended March 31, 2020
48,408,587	34,723,789
1,092,520	1,596,453
4,228,747	2,968,146
2,280,000	2,640,000
<b>56,009,854</b>	<b>41,928,388</b>

23 Depreciation and amortisation expense

Depreciation on tangible assets [Refer note 11(a)]

Year ended March 31, 2021	Year ended March 31, 2020
27,798,079	23,392,918

For AMBEY LABORATORIES LIMITED

*[Signature]*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*[Signature]*  
DIRECTOR



**Ambey Laboratories Limited**  
**Statement of Profit and Loss for the year ended 31st March, 2021**  
 (All amounts are in Indian Rupees, unless otherwise stated)

Depreciation on intangible assets [Refer note 11(b)]	4,424,164	148,107
<b>Total</b>	<b>32,222,243</b>	<b>23,541,025</b>

	Year ended March 31, 2021	Year ended March 31, 2020
<b>24 Finance cost</b>		
Interest expense		
On term Loan	40,953,318	49,483,889
On vehicle Loan	-	39,517
Bank charges	149,491	761,103
<b>Total</b>	<b>41,102,809</b>	<b>50,284,509</b>

For AMBEY LABORATORIES LIMITED  
*AA in Cemy*  
 DIRECTOR

For AMBEY LABORATORIES LIMITED  
*Arun Goyal*  
 DIRECTOR



Ambey Laboratories Limited

Statement of Profit and Loss for the year ended 31st March, 2021

(All amounts are in Indian Rupees, unless otherwise stated)

Schedule of Fixed Assets as per Income Tax Act, 1961 as on 31st March, 2021

Particulars	Rate Of Dep.	WDV as on 01.04.20	Addition		Sale/ Adj.	Total	Depreciation	WDV as on 31.03.21
			More than 180 days	Less than 180 days				
Plant & Machinery	15%	114,867,531	2,739,147	4,089,647	-	121,696,325	17,947,725	103,748,600
Office Equipments	15%	-	35,416	250,744	-	286,160	24,118	262,042
Furniture & Fittings	10%	1,990,717	-	523,800	-	2,514,517	225,262	2,289,255
Computer & Computer Peripherals	40%	62,530	-	117,158	-	179,688	48,443	131,244
Building	10%	59,070,303	287,674	2,179,799	-	61,537,776	6,044,788	55,492,988
Computer Software	25%	60,268	-	-	-	60,268	15,067	45,201
<b>TOTAL</b>		<b>176,051,349</b>	<b>3,062,237</b>	<b>7,161,148</b>	<b>-</b>	<b>186,274,734</b>	<b>24,305,403</b>	<b>161,969,330</b>

For AMBEY LABORATORIES LIMITED For AMBEY LABORATORIES LIMITED

*M. D. N. V.*  
DIRECTOR

*A. S. S. S.*  
DIRECTOR



Ambey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

25 Other expenses	Year ended March 31, 2021	Year ended March 31, 2020
Audit remuneration (Refer note below)	50,000	50,000
Advertisement expenses	53,000	93,932
Business promotion expenses	1,251,954	2,350,841
Bad debts	5,377,008	15,885,888
Documentation expenses	116,750	-
Communication expenses	365,868	227,583
Commission Expenses	2,301,030	276,350
Research & development Expenditure	204,994	-
Donation expenses	7,950	142,320
Electricity expenses	899,062	479,617
Testing expenses	191,344	-
Freight outward	6,919,265	5,233,015
Insurance expenses	609,270	764,121
Legal & professional expenses	2,672,537	1,899,733
Office expenses	532,560	188,541
Printing & stationery	187,607	136,547
Rates and taxes	1,864,738	842,702
Repair & maintenance		
-Building	3,666,410	57,509
-Others	52,870	2,602,345
Rental expenses	7,492,294	7,864,358
Travelling and conveyance expenses	1,614,439	4,620,096
Vehicle Running & Maintenance	314,313	882,829
Other miscellaneous expenses	750,116	704,719
<b>Total</b>	<b>37,495,380</b>	<b>45,303,046</b>

Note :

(a) The following is the break-up of Auditors remuneration (exclusive of GST)

As auditor:		
Statutory audit	50,000	50,000
Other matter	37,167	-
<b>Total</b>	<b>87,167</b>	<b>50,000</b>

For AMBEY LABORATORIES LIMITED

*AA. Gupta*  
DIRECTOR

For AMBEY LABORATORIES LIMITED

*Arun Gupta*  
DIRECTOR



Ambey Laboratories Limited  
Statement of Profit and Loss for the year ended 31st March, 2021  
(All amounts are in Indian Rupees, unless otherwise stated)

	March 31, 2021	March 31, 2020
<b>26 Expenditure in foreign currency (On Accrual basis)</b>		
Commission expenses	1,091,567	-
<b>Total</b>	<b>1,091,567</b>	<b>-</b>
<b>27 Earnings per share (EPS)</b>		
	March 31, 2021	March 31, 2020
Profit/ (loss) after tax attributable to equity shareholders	29,145,173	2,160,373
Weighted average number of equity shares (In numbers)	489,350	489,350
Nominal value of equity shares (In Rs.)	100	100
Basic earnings/ (loss) per share (In Rs.)	59.56	4.41
Diluted earnings/ (loss) per share (In Rs.)	59.56	4.41

**28 Related party disclosures**

In accordance with the requirement of Accounting Standard (AS)- 18 on "Related Party Disclosures" the names of the related parties where control exists /able to exercise significant influence along with the aggregate transactions/year end balances with them as identified and certified by the management are given below:

**(a) Names of the related parties and related party relationship**

- i Key Management Personnel (KMP):  
Anil Gupta  
Archit Gupta  
Arpit Gupta
- ii Entities under common control of KMP:  
Aromatic Rasayan Pvt Ltd
- iii Relatives of KMP:  
Rishita Gupta  
Achala Gupta  
Sarina Gupta

**(b) Transaction with related Parties:**

	Year ended March 31, 2021	Year ended March 31, 2020
<b>Aromatic Rasayan Pvt Ltd</b>		
Sale of goods	409,457,861	0
Purchase of goods	287,823,864	7,920,314
Rent paid	402,000	90,000
<b>Director Remuneration</b>		
Anil Gupta	840,000	960,000
Archit Gupta	720,000	840,000
Arpit Gupta	720,000	840,000
<b>Salary paid</b>		
Rishita Gupta	480,000	480,000
Achala Gupta	480,000	480,000
Sarina Gupta	480,000	480,000

**29 Previous year's figures**

Previous year's figures have been regrouped/ reclassified to conform with the current year's classification/ presentation, wherever applicable.

As per our report of even date.

For Sastry K Anandam & Co, LLP  
Chartered Accountants  
Firm Registration No. 000179N/N500051

CA Krishna Kumar  
(Partner)  
M.No. 514021

Place : New Delhi  
Date : 02.09.2021

For and on behalf of the Board of Directors of  
Ambey Laboratories Limited  
CIN: U74899DL1985PLC020490

For AMBEY LABORATORIES LIMITED

Arpit Gupta  
Director  
DIN: 01876092

Place : New Delhi  
Date : 02.09.2021

Archit Gupta  
Director  
DIN: 00378409

Place : New Delhi  
Date : 02.09.2021

DIRECTOR

**Ambey Laboratories Limited**  
**Statement of Profit and Loss for the year ended 31st March, 2021**  
(All amounts are in Indian Rupees, unless otherwise stated)

	March 31, 2021	March 31, 2020
<b>Calculation of Deferred Tax</b>		
WDV as per income tax act	161,969,330	179,622,760
WDV as per companies act	158,485,290	180,484,149
<b>Total Difference</b>	<b>3,484,040</b>	<b>(861,390)</b>
Deferred tax asset created @ 26%	905,850	(223,961)
Unabsorbed Depreciation & Losses	-	-
Deferred tax asset @ 26%	-	-
<b>Net deferred tax asset</b>	<b>(905,850)</b>	<b>223,961</b>

For AMBEY LABORATORIES LIMITED

For AMBEY LABORATORIES LIMITED

*AA Anandam*  
DIRECTOR

*Aravind*  
DIRECTOR

